Evidence map›Paper›PMID 41191157›Full record

Trial reportJournal of neuro-oncology2025

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy.

Debra Nana Yeboa, Benjamin T Whitfield, Ruitao Lin, Chinenye Lynette Ejezie, Todd A Swanson, Thomas H Beckham, Chenyang Wang, Brian De, Subha Perni, Martin C Tom and 26 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Debra Nana YeboaDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. dnyeboa@mdanderson.org.
Benjamin T WhitfieldDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruitao LinDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chinenye Lynette EjezieDepartment of Health Sciences, Towson University, Towson, MD, USA.
Todd A SwansonDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thomas H BeckhamDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chenyang WangDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brian DeDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Subha PerniDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Martin C TomDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jing LiDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Susan L McGovernDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca HarrisonDivision of Neurology, University of British Columbia, Vancouver, Canada.
Nazanin K MajdDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vinay K PuduvalliDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashley E AaroeDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Monica LoghinDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Barbara J O'BrienDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anuj D PatelDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chirag B PatelDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey S WefelDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ceylan Altintas TaslicayQuantitative Imaging Analysis Core, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria Gule-MonroeDepartment of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Arnold C PaulinoDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mary Frances McAleerDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David R GrosshansDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amol J GhiaDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wen JiangDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Caroline ChungDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Moshe MaorDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cheng-Han YangDepartment of Biostatistics, Yale University, New Haven, CT, USA.
Maria A GubbiottiDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carlos Kamiya-MatsuokaDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leomar Y BallesterDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shiao-Pei WeathersDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason T HuseDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMolecular glioblastoma (molGBM) is a variant lacking the full histopathological profile of glioblastoma. We report a trial aimed at addressing the optimal management of this newly recognized rarer form of glioma.

methodsIn this phase II study, molGBM patients were treated with radiation to a dose of 60Gy to the gross tumor volume (GTV) only, and a single smaller margin potentially as low as 1cm to the clinical tumor volume (CTV). As the trial is ongoing, we report on important exploratory biomarker findings correlating with median overall survival (mOS). Analysis included Kaplan-Meier and univariable/multivariable cox proportional hazard models. Available pre-operative tissue was subjected to epigenetic/DNA methylation profiling on the Infinium EPIC platform.

resultsFrom 2019 to 2023, 25 patients were enrolled based on initial pathology review, with 23 identified on 2nd review as grade 2 and 3 disease. 74% of patients received concurrent chemoradiotherapy with adjuvant chemotherapy. Of 9 patients with profiling, 5 were classified as mesenchymal subtype, while 4 matched to a variety of other phenotypes, including a novel F type GBM. Despite similar histological appearance corresponding to "lower grade glioma", molGBM classified as IDH-wildtype mesenchymal had mOS of 15.7 months (95% CI 15.5-NA) while the other tumors had a mOS of 37.7 months (95% CI 10.9-NA).

conclusionOur results demonstrate underlying heterogeneity within the molGBM population, pointing to future hypothesis-generating risk stratification strategies. We also demonstrate the feasibility of CTV reduction with therapy intensification to set a practice standard for RT management of non-enhancing molGBM.

Indexed as

Brain NeoplasmsChemoradiotherapyGlioblastomaAdultAgedDNA MethylationEpigenesis, GeneticFemaleFollow-Up StudiesHumansIsocitrate DehydrogenaseMaleMargins of ExcisionMiddle AgedProspective StudiesTreatment OutcomeIsocitrate DehydrogenaseChemoradiotherapyMolecular glioblastomaMolecular WHO grade 4 gliomaNon-enhancingSurvival

Identifiers

PMID41191157
PMCPMC12589214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.